Compare ACAD & AVNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACAD | AVNT |
|---|---|---|
| Founded | 1993 | 1927 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 4.1B |
| IPO Year | 2000 | 2000 |
| Metric | ACAD | AVNT |
|---|---|---|
| Price | $17.18 | $43.01 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 8 |
| Target Price | $30.21 | ★ $53.13 |
| AVG Volume (30 Days) | ★ 2.4M | 651.6K |
| Earning Date | 11-04-2026 | 11-04-2026 |
| Dividend Yield | N/A | ★ 2.61% |
| EPS Growth | ★ 69.12 | N/A |
| EPS | 0.51 | ★ 1.77 |
| Revenue | $726,437,000.00 | ★ $3,835,500,000.00 |
| Revenue This Year | $19.55 | $6.78 |
| Revenue Next Year | $13.34 | $4.02 |
| P/E Ratio | $34.47 | ★ $24.48 |
| Revenue Growth | ★ 40.45 | 1.71 |
| 52 Week Low | $15.86 | $28.50 |
| 52 Week High | $30.96 | $49.08 |
| Indicator | ACAD | AVNT |
|---|---|---|
| Relative Strength Index (RSI) | 34.82 | 47.34 |
| Support Level | $15.86 | $35.57 |
| Resistance Level | $22.71 | $46.11 |
| Average True Range (ATR) | 1.20 | 1.42 |
| MACD | -0.11 | -0.34 |
| Stochastic Oscillator | 18.38 | 2.67 |
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.
Avient Corp manufactures and sells various chemical and plastic-based products to designers and plastic processors. The firm operates in two reportable segments: Color, Additives and Inks, and Specialty Engineered Materials. The company's product portfolio includes concentrated color and ink blends, plastic resins, and various specialized polymer materials used in industries such as food packaging, construction, transportation, cosmetics, and healthcare. The Color, Additives, and Inks segment and the distribution segment generate maximum revenue. Geographically, the company generates maximum revenue from the United States and Canada, followed by EMEA, Asia, and Latin America.